Search Results

Theseus Pharmaceuticals, Inc. today announced that Concentra Biosciences, LLC (“Concentra”) through its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET.

As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock.

Theseus Pharmaceuticals, Inc. today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC (“Concentra”) will acquire Theseus for a price per share of Theseus common stock.

Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox family biologics, announced a Good Manufacturing Practice- plasmid DNA contract development and manufacturing organization agreement.

Theseus Pharmaceuticals, Inc. today announced that the company will participate virtually in the following upcoming investor conferences.

Theseus Pharmaceuticals, Inc. announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8th at 10:30am ET.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal stromal tumors (GIST).

Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC.